| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SLAMF6; KALI; NTBA; KALIb; Ly108; NTB-A; SF2000 |
| Entrez GeneID | 114836 |
| clone | 2F1C9 |
| WB Predicted band size | 37.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD352 (AA: extra 22-226) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD352抗体的3篇示例参考文献(注：文献为虚拟示例，实际引用需查询真实数据库)：
---
1. **文献名称**：*CD352 Antibody Blocks T Cell Exhaustion in Chronic Viral Infection*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种靶向CD352的单克隆抗体，并验证其在慢性病毒感染模型中对T细胞耗竭的逆转作用。实验表明，该抗体通过增强T细胞受体信号通路，恢复耗竭T细胞的抗病毒功能，为免疫治疗提供新策略。
---
2. **文献名称**：*Structural Characterization of CD352 Epitopes Using Humanized Antibodies*
**作者**：Chen L, et al.
**摘要**：通过X射线晶体学解析CD352与其人源化抗体的复合结构，揭示了抗体结合的关键表位区域。研究为优化CD352靶向治疗抗体的设计提供了分子基础。
---
3. **文献名称**：*CD362 Antibody Enhances NK Cell-Mediated Tumor Immunity*
**作者**：Wang Y, et al.
**摘要**：研究发现抗CD352抗体可通过激活NK细胞的SLAMF6信号通路，显著提升其对实体瘤细胞的杀伤能力。动物模型显示，联合PD-1抑制剂可协同抑制肿瘤生长。
---
**提示**：实际研究中建议通过PubMed、Web of Science等平台，以“CD352 antibody”、“SLAMF6 therapeutic”等关键词检索最新文献，并优先选择高影响力期刊的论文。
CD352. also known as SLAMF6 or NTB-A, is a cell surface glycoprotein belonging to the signaling lymphocytic activation molecule (SLAM) family. It functions as a self-ligand receptor expressed on various immune cells, including T cells, natural killer (NK) cells, B cells, and dendritic cells. Structurally, CD352 contains immunoglobulin-like domains, a transmembrane region, and cytoplasmic tyrosine-based signaling motifs (ITSMs) that recruit phosphatases like SHP-1/2 or adaptor proteins to modulate immune responses.
CD352 plays dual roles in immune regulation, acting as a co-stimulatory or co-inhibitory molecule depending on cellular context. It facilitates cell-cell interactions, particularly in lymphocyte activation, adhesion, and cytotoxicity. In T cells, CD352 engagement fine-tunes T-cell receptor (TCR) signaling, impacting effector functions and exhaustion. Studies highlight its involvement in chronic viral infections (e.g., HIV, HCV) and cancer, where sustained CD352 expression correlates with T-cell dysfunction.
Antibodies targeting CD352 are research tools or potential therapeutics. Blocking CD352 may restore anti-tumor immunity or mitigate autoimmune reactions by altering signaling pathways. Conversely, agonist antibodies might enhance immune activation in specific contexts. Its role as a biomarker for immune cell states (e.g., exhausted T cells) further underscores clinical relevance. Research continues to explore CD352's mechanistic nuances and therapeutic targeting in immunotherapy and immune-related disorders.
×
